Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cytokinetics (Nasdaq: CYTK) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Monday, April 7, 2025, at 2:15 PM Eastern Time.
Investors and interested parties can access the live webcast through the Investors & Media section of Cytokinetics' website. The webcast recording will remain available on the company's website for 90 days after the event concludes.
Cytokinetics (Nasdaq: CYTK) ha annunciato la sua prossima partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. Il team di gestione dell'azienda parteciperà a una chiacchierata informale programmata per lunedì 7 aprile 2025, alle 14:15 ora orientale.
Gli investitori e le parti interessate possono accedere alla diretta web attraverso la sezione Investitori & Media del sito web di Cytokinetics. La registrazione della diretta rimarrà disponibile sul sito dell'azienda per 90 giorni dopo la conclusione dell'evento.
Cytokinetics (Nasdaq: CYTK) ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham. El equipo de gestión de la compañía participará en una charla informal programada para el lunes 7 de abril de 2025, a las 2:15 PM hora del Este.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores y Medios del sito web de Cytokinetics. La grabación de la transmisión estará disponible en el sitio web de la empresa durante 90 días después de que concluya el evento.
사이토키네틱스 (Nasdaq: CYTK)는 제24회 니드햄 연례 가상 의료 회의에 참여할 예정이라고 발표했습니다. 회사의 경영진 팀은 2025년 4월 7일 월요일, 동부 표준시 오후 2시 15분에 예정된 대담에 참여할 것입니다.
투자자 및 관심 있는 당사자는 사이토키네틱스 웹사이트의 투자자 및 미디어 섹션을 통해 라이브 웹캐스트에 접근할 수 있습니다. 웹캐스트 녹화는 이벤트가 종료된 후 90일 동안 회사 웹사이트에서 이용할 수 있습니다.
Cytokinetics (Nasdaq: CYTK) a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour le lundi 7 avril 2025, à 14h15 heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section Investisseurs & Médias du site web de Cytokinetics. L'enregistrement de la diffusion restera disponible sur le site de l'entreprise pendant 90 jours après la fin de l'événement.
Cytokinetics (Nasdaq: CYTK) hat seine bevorstehende Teilnahme an der 24. Jahreskonferenz für virtuelle Gesundheitsversorgung von Needham bekannt gegeben. Das Management-Team des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Montag, den 7. April 2025, um 14:15 Uhr Eastern Time geplant ist.
Investoren und interessierte Parteien können die Live-Übertragung über den Bereich Investoren & Medien der Website von Cytokinetics abrufen. Die Aufzeichnung der Übertragung bleibt 90 Tage nach dem Ende der Veranstaltung auf der Unternehmenswebsite verfügbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty biopharmaceutical company building on its over 25-years of pioneering scientific innovation with intention to create a muscle biology franchise business focused on medicines designed to optimize muscle performance for patients with cardiac and other diseases of muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is Cytokinetics (CYTK) presenting at the Needham Healthcare Conference 2025?
How can investors watch Cytokinetics' (CYTK) Needham Conference presentation?
How long will CYTK's Needham Conference presentation replay be available?
What type of presentation will CYTK deliver at the Needham Healthcare Conference?
